Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can one imagine if we are the 10% share holders of aphria and in on the take over. What does it all mean... ugh my brain is going to explode. GLA
Man some crazy shift happening these days. Greed will take em all down.
Still think We have the better candidate? Man that would have been fun.
Yes that is a concern, Alphria recieved 5% in stock and Lots of Cash from Emblem already for that 5-Year agreement, Niether CEO has Mentioned any of this or the 4-1 Split on Alefia. Good Day...
Ndakota
Couldn't agree with you more. If the 1 for 4 split occurs before the swap I think Emblem holders make out like Kings. If it happens after the swap, we get screwed in the deal and I see legal action against Aleafia taking place in that situation. Hoping that the supply agreement with Aphria pans out, without something big happening to Aphria as they do have quite the battle going on.
Personally I feel this has no effect on US investors. I feel that the merger is good despite what I feel to be an undervalued buyout. But I reiterate that a 27% premium from price at the time is still a decent premium. Just wish Emblem would have executed differently and attracted a bigger investor.
Merry Christmas everyone. :)
Here is the thing. Unless they are developing cancer type cures recreational is also a good way to go. Bigger is always better. But I believe the food industry and beverage is going to be the biggest winner. Everyone eats and let face it safer to ingest than inhale. Butter is used for all Kinds of recipes. Still think NickI Dean sold us out and made us some ones bitch. All I know is that I am down over 60% and don't want to chase any of this bull shit. Trump is about to F shit up good for all investors. I just want to make my money back so I can stop stressing bout this nonsense. GLA
I live in South Carolina, they have outdoor Grows here, that IMHO is not a Bad Move. My concern, is the Split that Alifia has already approved for their share Holders Not US.. At this point I feel bigger is Better and the focus of the two is on the Medical side along with other Countries Germany and Scottish and the ability of being in the Legal Cannabis space is a Plus when it comes to Rev.
This is the youngest Industry out there and They both seem to be Standing on there own Two Feet...Time will Tell..Good Day...
Ndakota
I have owned this company way before it went public only good thing i can say is i got in at the lowest cost anyone has seen until now . I am truly disgusted by the fake ass CEO nikki dean , He cant even answer anyone truthfully , its always spin and crafted marketing language . he needs to resign ASAP as he is to incompetent to be a CEO
What concerns me, is during that interview, they are now pursuing an out door grow, looking to make .25 cents a gram, lol, even the interviewer was coughing it back up, lol
They did this now, to keep the price tag down, if they would have waited til after the Q-4 report, the price to buy emblem would have been twice what they offered, I will agree on the aphria, they seem to have there own problems. they do still have a rather large supply agreement that runs for 5 years. 175,000 Kgrams, already paid for in full i do believe.
I along with many expected Consolidation Aleafia, does not seem to be as stable or set for growth as Emblem seemed to be..
the Question on the Aleafia 1 for 4 reverse split still bothers me, they have passed it and We deserve to know how that is going to be played out... Good Day...
Ndakota
Any idea on how this effects US otc shareholders?
This buyout and merger builds a bigger stronger company....and although I agree that Emblem was worth more, but a 27% premium on the buyout is a nice premium. Can't wrap my head around how both companies are down on that news.
Aleafia at this point is the better buyout. Aphria is facing some serious allegations and potential legal scrutiny.
We need an in into the US. Go $emblem
Once again, market rejects value and shows Emblem is but a shiny turd. This was over as soon as they announced a marketing guy as their CEO. Anyone dumb enough to think Symbl was a good name for a recreational brand was smoking their product laced with tar. Lmao, enjoy, should have traded and not dated!
Aleafia Health and Emblem Corp. with CEOs Geoffrey Benic (CVE: $ALEF ) & Nick Dean (CVE: $EMC ) Midas Letter Interview post merger announcement
There is still approval
Additional Transaction Details
The Transaction will be effected by way of a court-approved plan of arrangement completed under the Canada Business Corporations Act and will require approval by at least 66 2/3% of the votes cast by the shareholders of Emblem present in person or by proxy at a special meeting of Emblem shareholders.
Upon completion of the Transaction, two (2) independent directors of Emblem will be appointed to serve on the board of directors of Aleafia, being Daniel Milliard and Loreto Grimaldi who will replace two (2) directors of Aleafia.
The Agreement includes customary provisions including reciprocal non-solicitation provisions, subject to the right of each of Emblem and Aleafia to accept a superior proposal/competing transaction in certain circumstances, with both Emblem and Aleafia having a seven (7) business day right to match any such superior proposal/competing transaction for the other party. The Agreement also provides for reciprocal termination fees of $10 million if the Transaction is terminated in certain specified circumstances.
In addition to shareholder approvals, the Transaction is subject to the receipt of certain regulatory, court and stock exchange approvals, the obtaining of material consents / waivers and the satisfaction of other conditions customary in transactions of this nature.
Aleafia has entered into support and voting agreements with each of Emblem’s directors, Emblem’s CEO and CFO, along with additional shareholders who have agreed to support and vote for the Transaction and who represent in aggregate approximately 11.8% of the outstanding Emblem shares.
It is expected that holders of Emblem options will receive replacement Aleafia options (on the same terms as the Emblem options), and holders of Emblem warrants will receive, upon exercise, the same consideration they would have received as if they were Emblem shareholders at the closing of the Transaction.
Aleafia and Emblem have also entered into an agreement with a holder representing 69.44% of the principal amount of Emblem’s convertible debentures pursuant to which such holder has agreed not to accept any change of control offer to the extent one is made, and the parties have agreed to use their commercially reasonable efforts to amend the trust indenture to amend the change of control provisions such that they do not apply to the Transaction, and to reduce the conversion price from $2.30 to $2.00.
Further information regarding the Transaction will be included in the information circular that Emblem will prepare, file, and mail in due course to its shareholders in connection with its special meeting to be held to consider the Transaction which is expected to occur before March 8, 2019. The Agreement will be filed on the SEDAR profiles of Emblem and Aleafia on the SEDAR website at www.sedar.com.
Emblem Board of Director’s Recommendations
The board of directors of Emblem (the “Emblem Board”) has unanimously determined, after receiving the unanimous recommendation of its Special Committee and financial and legal advice, that the consideration to be received by the Emblem shareholders is fair from a financial point of view and that the Arrangement is in the best interests of Emblem and its security holders, and the Emblem Board unanimously recommends that the Emblem shareholders vote in favour of the Transaction.
The Emblem Board and its Special Committee have each obtained a fairness opinion from Eight Capital and Echelon Wealth Partners Inc., respectively, that, as of the date of the opinions, and subject to the assumptions, limitations, and qualifications on which such opinions are based, the consideration to be received by Emblem shareholders pursuant to the Agreement is fair, from a financial point of view, to the Emblem shareholders.
Legal and Financial Advisors
Gowling WLG (Canada) LLP is acting as legal counsel to Aleafia. Deloitte advised Aleafia on financial due diligence. Mackie Research Capital Corporation is acting as financial advisor to Aleafia. In addition to other fees and expenses payable to Mackie, Aleafia is required to pay a success fee (the “Success Fee”) to Mackie upon closing of the Transaction equal to 2.0% of the aggregate fair market value of the share consideration issuable by Aleafia to Emblem’s shareholders and the amount of net debt of Emblem (as of its most recent balance sheet prior to the closing of the Transaction, and calculated as the sum of the long term debt and debentures) which is assumed or acquired by Aleafia, or retired or otherwise extinguished in connection with the Transaction (expected to be $30.5 million). The Success Fee is payable in common shares of Aleafia subject to acceptance of the TSX Venture Exchange.
Dentons Canada LLP is acting as legal counsel to Emblem. Eight Capital is acting as financial advisor to Emblem and Echelon Wealth Partners Inc. is acting as financial advisor to the Special Committee. Eight Capital and Echelon Wealth Partners Inc. have each provided a fairness opinion to the Emblem Board and the Special Committee, respectively.
Conference Call and Slide Presentation
Aleafia and Emblem will hold a webcast conference call, including a slide presentation, to discuss the Transaction.
Date: Wednesday December 19, 2018
Time: 8:30am (Toronto Time)
USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 9579635
International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 9579635
Webcast Link: https://edge.media-server.com/m6/p/4pcbtcdd
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast, however questions to management may only be submitted via the webcast.
For Additional Information and Support:
Aleafia Health Inc.
Emblem Corp.
Nicholas Bergamini
VP Public Affairs, Aleafia Health Inc.
416-860-5665
ir@aleafiainc.com
Morgan Cates
H+K Strategies
416-413-4649
morgan.cates@hkstrategies.ca
Alex Stojanovic
Chief Financial Officer, Emblem Corp.
647-748-9696
investors@emblemcorp.com
How or Who takes a Vote by show of hand? it makes you believe there where 10 people in the room, which I'm starting to Believe. They have 145,518,815 shares Emblem Has 130,600,000, we generated More Rev. then they Have, what the heck Just Happened?????
Think we still have a vote can mail in. I vote no. Id almost rather see them struggle and make something better happen. Also I believe we were told one thing then they did another thing on more than one occasion. I think some type of suit might be in order. What the hell did they give all their cash away? Or did the greedy old bastards decide they needed to fraud us. Let me know when the law suit happens.
We've been sold out? Aleafia on Nov.2018 set a special election to convert there O/S of 145,518,851, to 36,379,712. Dec. 06 2018 passed the Management info Circular by a show of Hands? They now have the ability to convert when they see fit?
Not only did Mr. Dean sell the company for PENNIES, he put the screws to the share Holder, How many of us bought under .80 cents? (Not many). We become a 40% of the company, which would allow them to go ahead with the 1-4 Conv. Under this Deal. We have been HAD.....Good Day...(My shares are worth Less then what I paid, just on the Buy out.), figure out a Rev.split on top of that. Thanks for looking out for Your supporters/Shareholders...
Ndakota
Emblem didn't execute their plan for expansion. This was a main reason why I invested. Had they followed through we would be much better off as a whole.
Was hoping alphria was going to buy us.
Is it 121 on top of current pps. Wtf. Hoping for better news than this.
Wondering How NICK/CEO explains to shareholders???
Agree I think it is 1.21 CAD and it does suck I'm a bag holder from when it IPO'd down 75 %
was hoping to at least break even.
I have 40,000 shares and was gonna add more this morning , but this news is pretty disappointing. If the offer is Canadian , it's horrible. If it's U.S., it's still crappy. Unless someone can convince me otherwise, I'd vote no. This is NOT what I expected from this company...I still feel it's a 5-10 dollar stock. This blows.
would you sell or stay with the new aleafia ?
Aleafia & Emblem Merger Presentation
https://cdn2.hubspot.net/hubfs/3928022/Aleafia%20&%20Emblem%20Presentation%20-%20Dec%2019,%202018.pdf
Is the offer of $1.21/ share Canadian or U.S. ? thanks (either way, it seems like a REALLY crappy deal)
Lmao, with 190,022,929 shares fully diluted looks like company value is current PPS, congrats!!! Lmao, saved from bankruptcy at least!
Aleafia Acquisition of Emblem Corp.is Tremendous Development
Aleafia Health Inc. to Acquire Emblem Corp. to Create New Medical Cannabis Leader
Combination will create Canada’s largest medical cannabis clinic network with access to 40 medical clinics and education centres;
Aleafia patients to access Emblem’s differentiated, high margin derivative products including capsules, oils and oral sprays, along with award-winning customer service and eCommerce platform;
Regulatory acceleration with Aleafia leveraging Emblem’s Health Canada License to extract and process medical cannabis products and sell them directly to patients;
Aleafia to become among national leaders in production capacity (including committed supply agreements);
Expansion of Aleafia’s national and global distribution platform;
Increased scale of the combined company will enhance its capital markets profile and increase trading liquidity; and
Combination results in current cash resources of approximately $70 million.
CLICK HERE TO VIEW THE ALEAFIA & EMBLEM PRESENTATION
TORONTO, December 19, 2018 – Aleafia Health Inc. (TSXV: ALEF) (“Aleafia” or the “Company”) and Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem”) are pleased to announce that they have entered into a definitive agreement (the “Agreement”) under which Aleafia will acquire, by way of a plan of arrangement under the Canada Business Corporations Act, all of Emblem’s issued and outstanding common shares in an all-share transaction currently valued at approximately $173.2 Million (the “Transaction”).
The Agreement calls for Emblem shareholders to receive 0.8377 of an Aleafia common share (each whole share, an “Aleafia Share”) in exchange for each Emblem common share (each, an “Emblem Share”), representing the equivalent of $1.21 per Emblem Share and a premium of 27.0% based on the closing prices of Aleafia and Emblem Shares on the TSX Venture Exchange (“TSXV”) on December 18, 2018. When the Transaction is completed, it is expected that existing Aleafia and Emblem shareholders will own approximately 59.0% and 41.0% of Aleafia, respectively, on a fully diluted in-the-money basis. The Transaction has been unanimously approved by Emblem’s Special Committee and Board of Directors.
Transaction Highlights
The proposed Transaction creates a new Canadian medical cannabis leader. It will operate the country’s largest national clinic network and enjoy improved operational scale with planned annual capacity of approximately 138,000 kg (including committed supply agreements), Canadian and expanded global distribution, and a robust branding and product development platform. Aleafia intends to capitalize on high growth opportunities and leverage international expansion across four verticals: Cannabis Production, Health and Wellness, Cannabis Education and the Consumer Experience.
The Leading Canadian Clinic Network: Combining Canabo Medical Clinic and GrowWise Health creates the leading Canadian clinic network with access to 40 national medical clinics and education centres that have served almost 60,000 patients, with increases in patient visits and referrals since October 17, 2018. In addition, Aleafia will be able to leverage Emblem’s extraction, and product innovation to, for the first time, sell high-margin medical cannabis directly to Aleafia’s patient base.
High-Margin, Highly Differentiated Medical Product Portfolio: Aleafia’s patient base will enjoy access to Emblem’s differentiated, high margin derivative products including capsules, oils and oral sprays, with among industry leading recognized revenue per gram rates. Patients will also access Emblem’s award-winning customer service, schedule home delivery and eCommerce platform.
Scaled Production Capacity and Leading Supply: Aleafia will be a leading licensed producer of cannabis with approximately 138,000 kg of production and supply across three Ontario facilities and the industry’s largest LP to LP cannabis supply agreement.
National and Global Distribution Platform: Aleafia expects to leverage Emblem’s approval to supply to the Provinces of Ontario, Saskatchewan, British Columbia and Alberta; national medical distribution through Shoppers Drug Mart; and national retail distribution through Fire & Flower, Starbuds and the emerging OnePlant network. In addition, through Emblem’s joint venture with German pharmaceutical wholesaler Acnos Pharma GmbH, Aleafia expects to access the world’s largest medical cannabis market serving more than 82 million people, with access to approximately 20,000 pharmacies, along with access to Australia’s burgeoning medical cannabis market upon completion of Aleafia’s previously announced transaction with CannaPacific Pty Ltd.
Industry Leading Adult-use Brands: Complementing Aleafia’s adult-use strategy via the transactions with Serruya Private Equity, Aleafia will leverage Emblem’s flagship brand Symbl, which is ranked one of the top selling recreational brands.
Focus on Product Development: Aleafia will build on Emblem’s product development success. Based out of Emblem’s state-of-the-art Product Innovation Centre, product development will focus on potential innovations in high-margin, branded beverages, edibles, vape pens, topicals and concentrates for the medical and adult-use markets.
Improved Capital Markets Profile: Aleafia will be a leading licensed producer appealing to a broader shareholder base, with greater access to capital and improved trading liquidity.
Robust Cash Position: Aleafia and Emblem currently have access to a combined CAD $69.9 million in cash, to be used for continued product innovation and brand building, construction and development of their cultivation facilities and outdoor grow operations, to support expansion efforts and to pursue strategic opportunities and investments that maximize shareholder value.
“The Emblem acquisition rapidly accelerates the execution of Aleafia’s strategy to become a vertically integrated, diversified cannabis company. It is difficult to overstate the significance of securing the highest quality medicine for our patients and Aleafia” said Aleafia Health CEO Geoffrey Benic. “Emblem’s product leadership in the medical and adult-use sectors and highly coveted supply agreements will perfectly complement Aleafia’s cannabis production and clinic operations. This is a transformative transaction that positions Aleafia as a global cannabis leader.”
“Emblem’s patient-focused product portfolio and strength in patient education, conversion and retention through GrowWise will be further bolstered by the patient acquisition capabilities of Aleafia’s Canabo clinics. The combination of the companies will form a fully integrated market leader in the medical cannabis sector, with industry leading patient counts, and the ability to immediately capitalize on full revenue potential,” said Emblem CEO Nick Dean. “Furthermore, our renowned national brands, robust footprint in emerging value-added products, and strong domestic and international growth opportunities, will cement our position of strength in this highly competitive market.”
Additional Transaction Details
The Transaction will be effected by way of a court-approved plan of arrangement completed under the Canada Business Corporations Act and will require approval by at least 66 2/3% of the votes cast by the shareholders of Emblem present in person or by proxy at a special meeting of Emblem shareholders.
Upon completion of the Transaction, two (2) independent directors of Emblem will be appointed to serve on the board of directors of Aleafia, being Daniel Milliard and Loreto Grimaldi who will replace two (2) directors of Aleafia.
The Agreement includes customary provisions including reciprocal non-solicitation provisions, subject to the right of each of Emblem and Aleafia to accept a superior proposal/competing transaction in certain circumstances, with both Emblem and Aleafia having a seven (7) business day right to match any such superior proposal/competing transaction for the other party. The Agreement also provides for reciprocal termination fees of $10 million if the Transaction is terminated in certain specified circumstances.
In addition to shareholder approvals, the Transaction is subject to the receipt of certain regulatory, court and stock exchange approvals, the obtaining of material consents / waivers and the satisfaction of other conditions customary in transactions of this nature.
Aleafia has entered into support and voting agreements with each of Emblem’s directors, Emblem’s CEO and CFO, along with additional shareholders who have agreed to support and vote for the Transaction and who represent in aggregate approximately 11.8% of the outstanding Emblem shares.
It is expected that holders of Emblem options will receive replacement Aleafia options (on the same terms as the Emblem options), and holders of Emblem warrants will receive, upon exercise, the same consideration they would have received as if they were Emblem shareholders at the closing of the Transaction.
Aleafia and Emblem have also entered into an agreement with a holder representing 69.44% of the principal amount of Emblem’s convertible debentures pursuant to which such holder has agreed not to accept any change of control offer to the extent one is made, and the parties have agreed to use their commercially reasonable efforts to amend the trust indenture to amend the change of control provisions such that they do not apply to the Transaction, and to reduce the conversion price from $2.30 to $2.00.
Further information regarding the Transaction will be included in the information circular that Emblem will prepare, file, and mail in due course to its shareholders in connection with its special meeting to be held to consider the Transaction which is expected to occur before March 8, 2019. The Agreement will be filed on the SEDAR profiles of Emblem and Aleafia on the SEDAR website at www.sedar.com.
Emblem Board of Director’s Recommendations
The board of directors of Emblem (the “Emblem Board”) has unanimously determined, after receiving the unanimous recommendation of its Special Committee and financial and legal advice, that the consideration to be received by the Emblem shareholders is fair from a financial point of view and that the Arrangement is in the best interests of Emblem and its security holders, and the Emblem Board unanimously recommends that the Emblem shareholders vote in favour of the Transaction.
The Emblem Board and its Special Committee have each obtained a fairness opinion from Eight Capital and Echelon Wealth Partners Inc., respectively, that, as of the date of the opinions, and subject to the assumptions, limitations, and qualifications on which such opinions are based, the consideration to be received by Emblem shareholders pursuant to the Agreement is fair, from a financial point of view, to the Emblem shareholders.
Legal and Financial Advisors
Gowling WLG (Canada) LLP is acting as legal counsel to Aleafia. Deloitte advised Aleafia on financial due diligence. Mackie Research Capital Corporation is acting as financial advisor to Aleafia. In addition to other fees and expenses payable to Mackie, Aleafia is required to pay a success fee (the “Success Fee”) to Mackie upon closing of the Transaction equal to 2.0% of the aggregate fair market value of the share consideration issuable by Aleafia to Emblem’s shareholders and the amount of net debt of Emblem (as of its most recent balance sheet prior to the closing of the Transaction, and calculated as the sum of the long term debt and debentures) which is assumed or acquired by Aleafia, or retired or otherwise extinguished in connection with the Transaction (expected to be $30.5 million). The Success Fee is payable in common shares of Aleafia subject to acceptance of the TSX Venture Exchange.
Dentons Canada LLP is acting as legal counsel to Emblem. Eight Capital is acting as financial advisor to Emblem and Echelon Wealth Partners Inc. is acting as financial advisor to the Special Committee. Eight Capital and Echelon Wealth Partners Inc. have each provided a fairness opinion to the Emblem Board and the Special Committee, respectively.
Conference Call and Slide Presentation
Aleafia and Emblem will hold a webcast conference call, including a slide presentation, to discuss the Transaction.
Date: Wednesday December 19, 2018
Time: 8:30am (Toronto Time)
USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 9579635
International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 9579635
Webcast Link: https://edge.media-server.com/m6/p/4pcbtcdd
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast, however questions to management may only be submitted via the webcast.
For Additional Information and Support:
Aleafia Health Inc.
Emblem Corp.
Nicholas Bergamini
VP Public Affairs, Aleafia Health Inc.
416-860-5665
ir@aleafiainc.com
Morgan Cates
H+K Strategies
416-413-4649
morgan.cates@hkstrategies.ca
Alex Stojanovic
Chief Financial Officer, Emblem Corp.
647-748-9696
investors@emblemcorp.com
About Aleafia Health Inc.
Aleafia is a leading, vertically integrated cannabis company with major cannabis cultivation & processing and medical cannabis clinics business operations. Aleafia owns two cannabis cultivation facilities, one of which is licensed and fully operational and one which will be fully operational in early 2019. Aleafia will reach a fully-funded annual growing capacity of 98,000 kg in 2019. Canabo Medical Clinics are the largest brick and mortar medical cannabis clinic network in Canada with 22 locations and over 50,000 patients.
About Emblem Corp.
Emblem is a fully integrated cannabis company focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Through its wholly-owned subsidiary Emblem Cannabis Corporation, Emblem is licensed to cultivate, process, and sell cannabis and cannabis derivatives in Canada under the Cannabis Act. Emblem’s state-of-the-art indoor cannabis cultivation facility and Product Innovation Centre is located in Paris, Ontario. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
For more information, please visit www.emblemcorp.com.
Aleafia Health Inc. to Acquire Emblem Corp. to Create New Medical Cannabis Leader
https://ih.advfn.com/stock-market/TSXV/EMC/stock-news/78917876/aleafia-health-inc-to-acquire-emblem-corp-to-cre
Aleafia buys Emblem for $173 Million
https://www.bnnbloomberg.ca/aleafia-to-buy-emblem-in-173m-all-stock-deal-as-pot-m-a-activity-warms-up-1.1185632
Charts are a good clue as well, everyear emmbf hits a low at this time, and shortly after new year it goes up, loaded 10k shares today at 71, hey that's the year I was born, I knew it was a good number, lol,
IMHO- They took a fair route on securing there Supply, They are Building and will have a State of the Art facility, for there Drug side and room for some Growing. This is a young Industry, i feel Emblem Corp is on a Good path, they have lined up More outlets all coming online in 2019, while still working to cover more area in Canada and Germany.
I feel there is Munipulation with the Shorts, which that to will End..Good Day....
Ndakota
Anyhow hoping for a big break 2019
Only as good as the tomatoes you bought. Classic example of tomatoes we bought just wrecked the PPs
Perfect example, who makes more, the guy growing the tomatoes, or the guy making the sauce? Tomatoes go bad, where as once the sauce is Jared, it sells for 5xs as much, and has 1000xs the shelf life,,,
Disagree, no money in growing, it will be like tiring to grow tomatoes for a living, lol, and I tried that,,,
Just seeing this a lot lately. The shorts are killing the pps and making it even easier to short. Then there will be no chance to recover with out lots of powder as they call it. They are gambling on one patent. They should have done their build out and grown their own supply. We will see. GL
Agree, you just never know when, hoping to have learned from the dot com boom, that only a few make it to the top, its almost like a mountain bike race to the top, however, you can pick your own path, and while even some of the biggest candain pot stocks want to grow for a living, emmbf, wants to create and build products, this I believe is the path to the top, most interested in this time release patent, I believe too, like emmbf will be a game changer, me and you have traded before, think this is our best find yet, a top notch real candain pot stock,
Not sure of your thinking outlook, Oct.17-Dec.31. All sales count in that time-frame. Q-4 runs 01 Oct. - 31 Dec. 2018, When sales are reported for Q-4 Numbers will be Much Higher, shorts are taking there chances now because they can. They too will run or ride the other way.
Reports out in the first 3-weeks of retail sales said Emblem was in the Top 3 in sales, they reported Patients recorded at the End of Q-3 was 4820. That count has already gone over 6,000 and Growing. Q-3 of 2019 we add Germany to our list of Medical Partners. lots of movement going on. These companies are in there Infant stages. IMHO the end of 2019 will show a Much Better Picture for Emblem and it's shareholders... Good Day..
Ndakota
Wish the morning trades would stop. MM's really want this to fail here. Can't keep up with the bleeding here. They have a great company shame shorters are so greedy. 6000 patients, time release mess and oils looking good. GLA
What happened here?? Seems like so much dilution somethings up why are we feeling
Good questions for sure, all I can say, is thc oil is the hottest selling thc product at the clubs where I live, and the price of weed continues to drop, so being emmbf is focused on products, I truly believe they are on the path to success, the day the time release pill hits the market, is the day you better own the most shares ever of emmbf, this is my number one stock!
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1282
|
Created
|
03/03/17
|
Type
|
Free
|
Moderators |
We love our Mothers! Finding the best Mother plant to breed each of our cannabis strains is the first step to uncovering the perfect phenotype. We begin by growing a full room of mothers of a single strain. We carefully watch each plant grow, taking note of their unique qualities. As each plant is harvested, it’s meticulously tested for the natural cannabinoids and terpenes that will provide the greatest patient relief. After the ultimate Mother phenotype is selected, we begin tending to her daughters with the same care and attention. Just as nature provides us with the benefits of cannabis, it has its own way of controlling the natural predators. Our first defense is a holistic one, using organic solutions to ensure our strains grow healthy and true to their innate plant powers. We also employ various strategies, like elevating the CO2 levels, making our plants grow bigger and more robust. The pungent terpene aroma and flavour is the telltale difference naturally grown makes.
We’re just like you. Either by chance, fate or on the advice of a physician, we discovered the medical benefits of cannabis. It naturally enhances our entire state of wellbeing for optimal living. That’s why we created Emblem. Together we can celebrate feeling whole, and a whole lot better than before. We’re not a giant, disconnected corporation. We’re a team of passionate growers carefully tending batches of thoughtfully curated cannabis strains, widely regarded for their efficacy, flavour and effect. We cultivate these strains into medical products that enhance your wellbeing, helping you transform your life and attain extraordinary health. Join us, for better living.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |